Emergence of extended spectrum-β-lactamase-producing escherichia coli O25b-ST131: A major community-acquired uropathogen in infants

Pediatric Infectious Disease Journal

Volumn 34, Issue 5, 2015, Pages 469-475

  Cheng, Ming Fang ^a,b   Chen, Wan Ling ^a,b,c   Hung, Wan Yu ^d   Huang, I Fei ^a,b   Chiou, Yee Hsuan ^a,b   Chen, Yao Shen ^a,b   Lee, Susan Shin Jung ^a,b   Hung, Chih Hsin ^d   Wang, Jiun Ling ^d,e  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c Kaohsiung Veteran General Hospital   (Taiwan)

^d I SHOU UNIVERSITY   (Taiwan)

^e E DA HOSPITAL   (Taiwan)

Author keywords

E. coli; extended spectrum lactamase; infant; ST131; urinary tract infection

Indexed keywords

AMIKACIN; AMPICILLIN; CARBAPENEM; CEFAZOLIN; CEFOXITIN; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; MINOCYCLINE; TIGECYCLINE; ANTIINFECTIVE AGENT; BETA LACTAMASE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL GENETICS; BACTERIUM ISOLATE; CLINICAL FEATURE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; FEMALE; FEVER; GENOTYPE; HUMAN; INFANT; INFANT DISEASE; MAJOR CLINICAL STUDY; MALE; MOLECULAR EPIDEMIOLOGY; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; URINARY TRACT INFECTION; COMMUNITY-ACQUIRED INFECTIONS; DRUG EFFECTS; ENZYMOLOGY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GENETICS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; RETROSPECTIVE STUDY; URINARY TRACT INFECTIONS;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; RETROSPECTIVE STUDIES; URINARY TRACT INFECTIONS;

EID: 84937393962     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000623     Document Type: Article

References (47)

1. Calbo E, Romaní V, Xercavins M, et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemother. 2006; 57: 780-783
2. Ena J, Arjona F, Martínez-Peinado C, et al. Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Urology. 2006; 68: 1169-1174
3. Johnson JR, Menard M, Johnston B, et al. Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. Antimicrob Agents Chemother. 2009; 53: 2733-2739
4. Moor CT, Roberts SA, Simmons G, et al. Extended-spectrum beta-lactamase (ESBL)-producing enterobacteria: factors associated with infection in the community setting, Auckland, New Zealand. J Hosp Infect. 2008; 68: 355-362
5. Blanc V, Leflon-Guibout V, Blanco J, et al. Prevalence of day-care centre children (France) with faecal CTX-M-producing Escherichia coli comprising O25b: H4 and O16: H5 ST131 strains. J Antimicrob Chemother. 2014; 69: 1231-1237
6. Chen PC, Yang CC, Wu CJ, et al. Factors predict prolonged wait time and longer duration of radiotherapy in patients with nasopharyngeal carcinoma: a multilevel analysis. PLoS One. 2014; 9: e109930
7. Guimarães B, Barreto A, Radhouani H, et al. Genetic detection of extendedspectrum beta-lactamase-containing Escherichia coli isolates and vancomycin- resistant enterococci in fecal samples of healthy children. Microb Drug Resist. 2009; 15: 211-216
8. Hibino S, Fukuchi K, Abe Y, et al. Four infants with upper urinary tract infection due to extended-spectrum bata lactamase (ESBL)-producing Escherichia coli. Kansenshogaku Zasshi. 2011; 85: 481-487
9. Ho WS, Balan G, Puthucheary S, et al. Prevalence and characterization of multidrug-resistant and extended-spectrum beta-lactamase-producing Escherichia coli from pediatric wards of a Malaysian hospital. Microb Drug Resist. 2012; 18: 408-416
10. Islam S. High rates of ESBL-producing Escherichia coli in young children who traveled recently to India. Pediatr Infect Dis J. 2012; 31: 1103
11. Oteo J, Cercenado E, Fernandez-Romero S, et al. Extended-spectrum-β- lactamase-producing Escherichia coli as a cause of pediatric infections: report of a neonatal intensive care unit outbreak due to a CTX-M-14- producing strain. Antimicrob Agents Chemother. 2012; 56: 54-58
12. Özçakar ZB, Yalçinkaya F, Kavaz A, et al. Urinary tract infections owing to ESBL-producing bacteria: microorganisms change-clinical pattern does not. Acta Paediatr. 2011; 100: e61-e64
13. Tartof SY, Solberg OD, Manges AR, et al. Analysis of a uropathogenic Escherichia coli clonal group by multilocus sequence typing. J Clin Microbiol. 2005; 43: 5860-5864
14. Weissman SJ, Adler A, Qin X, et al. Emergence of extended-spectrum β-lactam resistance among Escherichia coli at a US academic children's hospital is clonal at the sequence type level for CTX-M-15, but not for CMY-2. Int J Antimicrob Agents. 2013; 41: 414-420
15. Rogers BA, Sidjabat HE, Paterson DL. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother. 2011; 66: 1-14
16. Coque TM, Novais A, Carattoli A, et al. Dissemination of clonally related Escherichia coli strains expressing extended-spectrum beta-lactamase CTXM- 15. Emerg Infect Dis. 2008; 14: 195-200
17. Johnson JR, Johnston B, Clabots C, et al. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis. 2010; 51: 286-294
18. Lau SH, Kaufmann ME, Livermore DM, et al. UK epidemic Escherichia coli strains A-E, with CTX-M-15 beta-lactamase, all belong to the international O25: H4-ST131 clone. J Antimicrob Chemother. 2008; 62: 1241-1244
19. Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, et al. Intercontinental emergence of Escherichia coli clone O25: H4-ST131 producing CTX-M-15. J Antimicrob Chemother. 2008; 61: 273-281
20. Peirano G, Pitout JD. Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25: H4. Int J Antimicrob Agents. 2010; 35: 316-321
21. Platell JL, Cobbold RN, Johnson JR, et al. Commonality among fluoroquinolone- resistant sequence type ST131 extraintestinal Escherichia coli isolates from humans and companion animals in Australia. Antimicrob Agents Chemother. 2011; 55: 3782-3787
22. Chung HC, Lai CH, Lin JN, et al. Bacteremia caused by extended-spectrum- β-lactamase-producing Escherichia coli sequence type ST131 and non- ST131 clones: comparison of demographic data, clinical features, and mortality. Antimicrob Agents Chemother. 2012; 56: 618-622
23. Dayan N, Dabbah H, Weissman I, et al. Urinary tract infections caused by community-acquired extended-spectrum beta-lactamase-producing and nonproducing bacteria: a comparative study. J Pediatr. 2013; 163: 1417-1421
24. López-Cerero L, Navarro MD, Bellido M, et al. Escherichia coli belonging to the worldwide emerging epidemic clonal group O25b/ST131: risk factors and clinical implications. J Antimicrob Chemother. 2014; 69: 809-814
25. Johnson JR, Anderson JT, Clabots C, et al. Within-household sharing of a fluoroquinolone-resistant Escherichia coli sequence type ST131 strain causing pediatric osteoarticular infection. Pediatr Infect Dis J. 2010; 29: 473-475
26. Clinical Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; 19th Informational supplement M100-S19. Wayne, PA: Clinical Laboratory Standards Institute, 2009
27. Clermont O, Lavollay M, Vimont S, et al. The CTX-M-15-producing Escherichia coli diffusing clone belongs to a highly virulent B2 phylogenetic subgroup. J Antimicrob Chemother. 2008; 61: 1024-1028
28. Sidjabat HE, Paterson DL, Adams-Haduch JM, et al. Molecular epidemiology of CTX-M-producing Escherichia coli isolates at a tertiary medical center in western Pennsylvania. Antimicrob Agents Chemother. 2009; 53: 4733-4739
29. Chia JH, Chu C, Su LH, et al. Development of a multiplex PCR and SHV melting-curve mutation detection system for detection of some SHV and CTX-M beta-lactamases of Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae in Taiwan. J Clin Microbiol. 2005; 43: 4486-4491
30. Dallenne C, Da Costa A, Decré D, et al. Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae. J Antimicrob Chemother. 2010; 65: 490-495
31. Díaz MA, Hernández-Bello JR, Rodríguez-Baño J, et al.; Spanish Group for Nosocomial Infections (GEIH). Diversity of Escherichia coli strains producing extended-spectrum beta-lactamases in Spain: second nationwide study. J Clin Microbiol. 2010; 48: 2840-2845
32. Topaloglu R, Er I, Dogan BG, et al. Risk factors in community-acquired urinary tract infections caused by ESBL-producing bacteria in children. Pediatr Nephrol. 2010; 25: 919-925
33. Kothari C, Gaind R, Singh LC, et al. Community acquisition of β-lactamase producing Enterobacteriaceae in neonatal gut. BMC Microbiol. 2013; 13: 136
34. Al-Mayahie SM. Phenotypic and genotypic comparison of ESBL production by vaginal Escherichia coli isolates from pregnant and non-pregnant women. Ann Clin Microbiol Antimicrob. 2013; 12: 7
35. Ho PL, Lo WU, Lai EL, et al. Escherichia coli O25b-ST131 is an important cause of antimicrobial-resistant infections in women with uncomplicated cystitis. J Antimicrob Chemother. 2012; 67: 2534-2535
36. Naumovski L, Quinn JP, Miyashiro D, et al. Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patients. Antimicrob Agents Chemother. 1992; 36: 1991-1996
37. Mora A, Blanco M, López C, et al. Emergence of clonal groups O1: HNMD- ST59, O15: H1-D-ST393, O20: H34/HNM-D-ST354, O25b: H4- B2-ST131 and ONT: H21,42-B1-ST101 among CTX-M-14-producing Escherichia coli clinical isolates in Galicia, northwest Spain. Int J Antimicrob Agents. 2011; 37: 16-21
38. Gibreel TM, Dodgson AR, Cheesbrough J, et al. Population structure, virulence potential and antibiotic susceptibility of uropathogenic Escherichia coli from Northwest England. J Antimicrob Chemother. 2012; 67: 346-356
39. Pitout JD. Extraintestinal pathogenic Escherichia coli: a combination of virulence with antibiotic resistance. Front Microbiol. 2012; 3: 9
40. Peirano G, Richardson D, Nigrin J, et al. High prevalence of ST131 isolates producing CTX-M-15 and CTX-M-14 among extended-spectrum-beta-lactamase- producing Escherichia coli isolates from Canada. Antimicrob Agents Chemother. 2010; 54: 1327-1330
41. Suzuki S, Shibata N, Yamane K, et al. Change in the prevalence of extendedspectrum- beta-lactamase-producing Escherichia coli in Japan by clonal spread. J Antimicrob Chemother. 2009; 63: 72-79
42. Oteo J, Diestra K, Juan C, et al.; Spanish Network in Infectious Pathology Project (REIPI). Extended-spectrum beta-lactamase-producing Escherichia coli in Spain belong to a large variety of multilocus sequence typing types, including ST10 complex/A, ST23 complex/A and ST131/B2. Int J Antimicrob Agents. 2009; 34: 173-176
43. Peirano G, van Der Bij AK, Gregson DB, et al. Molecular epidemiology over an 11-year period (2000 to 2010) of extended-spectrum beta-lactamaseproducing Escherichia coli causing bacteremia in a centralized Canadian region. J Clin Microbiol. 2012; 50: 294-299
44. Shin J, Kim DH, Ko KS. Comparison of CTX-M-14- and CTX-M-15- producing Escherichia coli and Klebsiella pneumoniae isolates from patients with bacteremia. J Infect. 2011; 63: 39-47
45. Clinical Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; 21st Informational supplement M100-S21. Wayne, PA: Clinical Laboratory Standards Institute, 2011
46. Downs SM. Technical report: urinary tract infections in febrile infants and young children. The Urinary Tract Subcommittee of the American Academy of Pediatrics Committee on Quality Improvement. Pediatrics. 1999; 103: e54
47. Sheng WH, Badal RE, Hsueh PR. SMART Program Distribution of extendedspectrum β-lactamases, AmpC β-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia- Pacific region: results of the study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother. 2013; 57: 2981-2988